Category:Eiji KAWAMINAMI
Appearance
Eiji KAWAMINAMI
Executive Summary
Eiji KAWAMINAMI is an inventor who has filed 2 patents. Their primary areas of innovation include HETEROCYCLIC COMPOUNDS (macromolecular compounds (2 patents), Antineoplastic agents (1 patents), HETEROCYCLIC COMPOUNDS (macromolecular compounds (1 patents), and they have worked with companies such as Astellas Pharma Inc. (2 patents). Their most frequent collaborators include (2 collaborations), (2 collaborations), (2 collaborations).
Patent Filing Activity
File:Eiji KAWAMINAMI Monthly Patent Applications.png
Technology Areas
File:Eiji KAWAMINAMI Top Technology Areas.png
List of Technology Areas
- C07D487/08 (HETEROCYCLIC COMPOUNDS (macromolecular compounds): 2 patents
- A61P35/00 (Antineoplastic agents): 1 patents
- C07D519/00 (HETEROCYCLIC COMPOUNDS (macromolecular compounds): 1 patents
Companies
File:Eiji KAWAMINAMI Top Companies.png
List of Companies
- Astellas Pharma Inc.: 2 patents
Collaborators
- Hiroki ISHIOKA (2 collaborations)
- Kenichi KAWAGUCHI (2 collaborations)
- Kazuyuki KURAMOTO (2 collaborations)
- Tomoyoshi IMAIZUMI (2 collaborations)
- Takahiro MORIKAWA (2 collaborations)
- Hisao HAMAGUCHI (2 collaborations)
- Sunao IMADA (2 collaborations)
- Mitsuaki OKUMURA (2 collaborations)
- Takeyuki NAGASHIMA (2 collaborations)
- Tomohiro YOSHINARI (1 collaborations)
- Hideyuki WATANABE (1 collaborations)
- Kohei INAMURA (1 collaborations)
- Ryo SATO (1 collaborations)
- Yohei SEKI (1 collaborations)
- Hiroki FUKUDOME (1 collaborations)
- Ikumi KURIWAKI (1 collaborations)
Subcategories
This category has the following 6 subcategories, out of 6 total.
E
H
K
T
Categories:
- Hiroki ISHIOKA
- Kenichi KAWAGUCHI
- Kazuyuki KURAMOTO
- Pages with broken file links
- Tomoyoshi IMAIZUMI
- Takahiro MORIKAWA
- Hisao HAMAGUCHI
- Sunao IMADA
- Mitsuaki OKUMURA
- Takeyuki NAGASHIMA
- Tomohiro YOSHINARI
- Hideyuki WATANABE
- Kohei INAMURA
- Ryo SATO
- Yohei SEKI
- Hiroki FUKUDOME
- Ikumi KURIWAKI
- Eiji KAWAMINAMI
- Inventors
- Inventors filing patents with Astellas Pharma Inc.